Roger A Moorehead (R A Moorehead)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 9

Top Topics

Advanced Non Small Cell Lung Cancer

Hodgkin Lymphoma

Gene Expression

Top Venues

Genes, chromosomes & cancer

International journal of molecular sciences

This page only lists publications with an associated author ORCID identifier.

Publications

Resh Carter, Jim J Petrik, Roger A Moorehead
Overexpression of miR-200s inhibits proliferation and invasion while increasing apoptosis in murine ovarian cancer cells. PloS one 19 (7) (2024)
Resh Carter, Jim J Petrik, Roger A Moorehead
Overexpression of miR-200s inhibits proliferation and invasion while increasing apoptosis in murine ovarian cancer cells. PloS one 19 (7) (2024)
Kaitlyn E Simpson, Christina A Staikos, Katrina L Watson, Roger A Moorehead
Loss of MXRA8 Delays Mammary Tumor Development and Impairs Metastasis. International journal of molecular sciences 24 (18) (2023)
Kaitlyn E Simpson, Katrina L Watson, Roger A Moorehead
Elevated Expression of miR-200c/141 in MDA-MB-231 Cells Suppresses MXRA8 Levels and Impairs Breast Cancer Growth and Metastasis In Vivo. Genes 13 (4) (2022)
K Simpson, G Conquer-van Heumen, K L Watson, M Roth, C J Martin, Roger A Moorehead
Re-expression of miR-200s in claudin-low mammary tumor cells alters cell shape and reduces proliferation and invasion potentially through modulating other miRNAs and SUZ12 regulated genes. Cancer cell international 21 (1) (2021)
Majesta J Roth, Roger A Moorehead
The miR-200 family in normal mammary gland development. BMC developmental biology 21 (1) (2021)
Katrina L Watson, Kristen Sauerzopf, Roger A Moorehead
Isolated Soy Protein Promotes Mammary Tumor Development Induced by the Type I Insulin-like Growth Factor Receptor in Transgenic Mice. Nutrition and cancer 73 (8) (2020)
Robert A Jones, Roger A Moorehead
Integrative analysis of copy number and gene expression data identifies potential oncogenic drivers that promote mammary tumor recurrence. Genes, chromosomes & cancer 58 (6) (2019)
Paige M Chorner, Roger A Moorehead
A-674563, a putative AKT1 inhibitor that also suppresses CDK2 activity, inhibits human NSCLC cell growth more effectively than the pan-AKT inhibitor, MK-2206. PloS one 13 (2) (2018)